Studies related to Serum DHEA and Ashwagandha

A Randomized, Double-Blind, Placebo-Controlled, Crossover Study Examining The Hormonal And Vitality Effects Of Ashwagandha ( Withania Somnifera) In Aging, Overweight Males

Effect Increase
Values (nmol/L) DHEA-S. Placebo: 8.27 (0.74). Ashwaganda: 9.76 (0.77)
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 57
Gender Male
Age Range 30-44, 45-64, 65+
Body Types Obese, Overweight
Notes for this study:
In a randomized, double-blind, placebo-controlled crossover trial, 57 overweight/obese men reporting fatigue or reduced vitality were assigned to take an ashwagandha extract containing 10.5 mg of withanolide glycosides or placebo for 8 weeks for each crossover condition with no washout period.

The primary outcome was the total score as assessed by the Ageing Males' Symptoms score, and there wasn't a notable difference between groups. Notable differences in fatigue and vigor. A modest statistically significant increase in testosterone and DHEA-S were found while taking ashwaganda, as compared with placebo, and no notable changes in cortisol or estradiol.

No notable adverse events were found.

A Standardized Withania Somnifera Extract Significantly Reduces Stress-Related Parameters in Chronically Stressed Humans: A Double-Blind, Randomized, Placebo-Controlled Study
Effect Increase
Values ug/dl. Placebo: before 166.7 (32.9), after 149.3 (35.6). 125 mg before 167.4 (37.8), after 189.5 (40.8). 250 mg before 152 (48.9), after 200.7 (54.6). 500 mg before 159.6 (61.7), after 212.1 (74.7)
Trial Design randomized
Trial Length 16months
Number of Subjects 130
Gender mixed
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 130 participants with an anxiety disorder were assigned to take 125 mg, 250 mg, or 500 mg of ashwagandha extract containing a minimum of 8% withanolide glycosides, 32% oligosaccharides, and a maximum of 2% withaferin A for 60 days. 32 participants dropped out, with more dropouts in the placebo group. While the placebo group saw no notable changes, the ashwaganda groups all saw statistically significant improvements compared with the placebo group in stress/anxiety, fatigue, flushing, perspiration, loss of appetite, headache and muscle pain, feelings of impending doom, palpitations, dry mouth, sleeplessness, forgetfulness, irritability, and inability to concentrate. The 250 mg and 500 mg groups seemed to be somewhat more potent than the 125 mg group for stress/anxiety, fatigue and inability to concentrate. Serum cortisol, CRP and serum VLDL-C, and blood pressure were statistically significantly reduced compared with placebo in all ashwagandha groups, and DHEAS was significantly increased. Fasting blood glucose, total serum cholesterol, serum triglycerides, LDL-C, and HDL-C were improved in the 250 mg and 500 mg groups compared with placebo, and the 500 mg group was significantly lower than the 125 mg group for all but CRP and fasting blood glucose.
Funding issues for this study:
"We would like to thank Natreon Inc. (New Brunswick, New Jersey) for financial support of this study. " "Dr. Auddy is an employee of Natreon Inc., which is the patent holder of Withania somnifera extract sold under the trade names Essentra® and Sensoril®. Dr. Abedon is an employee of NutraGenesis LLC, which sells Withania somnifera extract exclusively under the trade names Essentra® and Sensoril®. Dr. Ghosal was an unpaid adviser to Natreon Inc. at the time the study was conducted."